Drug Profile

GSK 3494245

Alternative Names: DDD-1305143; GSK-3494245

Latest Information Update: 22 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline; University of Dundee
Developer GSK
Class Antiprotozoals; Small molecules
Mechanism of Action Proteasome inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Leishmaniasis

Most Recent Events

30 Jun 2024 Discontinued - Phase-I for Leishmaniasis (In volunteers, In adults) in United Kingdom (PO) (GSK pipeline, October 2024)
11 Jan 2024 GlaxoSmithKline completes a phase I first in human study in Leishmaniasis (In Volunteers) in United Kigndom (PO) (NCT04504435) (EudraCT2019-004492-39)
08 Nov 2023 GSK 3494245 is still in phase I trials for Leishmaniasis (In volunteers, In adults) in United Kingdom (PO) (NCT04504435)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com